Newsroom | 45263 results
Sorted by: Latest
-
Resumen: Alnylam recibe la aprobación de la Comisión Europea para AMVUTTRA® (vutrisiran) en el tratamiento de la amiloidosis ATTR con miocardiopatía
CAMBRIDGE, Massachusetts--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), la compañía líder en terapias de ARN de interferencia (ARNi), ha anunciado hoy que la Comisión Europea (CE) ha concedido la aprobación para el tratamiento de la amiloidosis de transtiretina común o hereditaria en pacientes adultos con cardiomiopatía (ATTR-CM) como indicación adicional para su terapia huérfana de ARNi AMVUTTRA® (vutrisiran). El comunicado en el idioma original es la versión oficial y autoriz...
-
20/20 Onsite Expands Mobile Vision Fleet, Strengthening Nationwide Reach and Clinical Trial Support Capacity
BOSTON--(BUSINESS WIRE)--20/20 Onsite, the leading provider of point-of-need ophthalmic services for clinical trials, announces the deployment of its latest mobile vision clinic, bringing its fleet to 16 units, including a mix of mobile clinics, pods, and suites. The new unit hit the road in early May and is now fully operational, enabling 20/20 Onsite to support a higher tempo of decentralized and hybrid clinical trials nationwide. This milestone reinforces 20/20 Onsite’s ability to scale with...
-
Agenus Announces Virtual Annual Shareholders Meeting
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (NASDAQ: AGEN), a leader in immuno-oncology innovation, today announced that its Annual Shareholders Meeting will begin at 10:30 a.m. ET on June 17, 2025, and will be conducted in a virtual format only. Registration for attendees will start at 10:15 a.m. ET. To participate in the Annual Shareholders Meeting, shareholders should visit www.virtualshareholdermeeting.com/AGEN2025 and enter the 16-digit control number found in their proxy mat...
-
EDETEK Engages Capgemini to Support Its Global Transformation Initiative and Accelerate AI Innovation in Clinical Development
NEW YORK--(BUSINESS WIRE)--EDETEK Inc., a global provider of leading AI-driven clinical development platforms and services, has engaged Capgemini to support its ongoing advancements in digital transformation within the life sciences industry. This engagement combines EDETEK’s deep domain expertise and established platforms and services with Capgemini’s advanced AI and engineering capabilities, to enable EDETEK to deliver innovative solutions aimed at optimizing clinical development, improving o...
-
Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application covering compositions of matter and methods of use for a novel class of aminated tryptamine derivatives. The patented compounds were...
-
MAIA Biotechnology to Present at BIO International Convention 2025
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology to Present at BIO International Convention 2025...
-
Novotech Showcased in Global Biotech Series for Innovation in Hepatitis B Research
SYDNEY--(BUSINESS WIRE)--Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company, is featured in The Next Frontier, a global branded series presented by the Biotechnology Innovation Organization (BIO) and produced by BBC StoryWorks Commercial Productions. The Next Frontier explores how biotechnology is addressing some of the world’s most urgent health and sustainability challenges. As part of the series, Novotech highlights its partnersh...
-
Novotech亮相全球生物技術專題系列片,展現B型肝炎研究創新成果
澳洲雪梨--(BUSINESS WIRE)--(美國商業資訊)-- Novotech作為一家可提供全方位服務的國際性受託研究機構 (CRO) 和科學諮詢公司,受邀參與由生物技術創新組織 (BIO) 推出、BBC StoryWorks商業製作公司製作的全球品牌專題系列片The Next Frontier)。 The Next Frontier深入探討了生物技術在因應全球健康危機與可持續發展挑戰方面發揮的作用。在系列片中,Novotech著重介紹了與Tune Therapeutics公司的緊密合作,雙方攜手推進慢性B型肝炎功能性治癒研究。全球有近3億人患有慢性B型肝炎。Novotech作為全球B肝臨床試驗領域的重要參與者,憑藉深厚的專業實力和國際執行力,協助委託方加速藥物開發和上市進程。 該專題片拍攝於紐西蘭,當地約有10萬名B型肝患者。國際知名肝病學家Edward Gane教授在片中介紹了Novotech與生物技術公司和中小型製藥企業的合作模式。專題片生動呈現了Novotech如何整合專家資源、精準鎖定受試者群體,憑藉在亞太地區、歐洲和北美地區建立的高效臨床試驗基礎設施,加速臨床開發進程...
-
诺为泰亮相全球生物技术专题系列片,展现乙肝研究创新成果
澳大利亚悉尼--(BUSINESS WIRE)--(美国商业资讯)-- Novotech(诺为泰)作为一家可提供全方位服务的国际性临床合同研究组织 (CRO) 和科学咨询公司,受邀参与由生物技术创新组织 (BIO) 推出、BBC StoryWorks商业工作室制作的全球品牌专题系列纪录片The Next Frontier。 The Next Frontier深入探讨了生物技术在应对全球健康危机与可持续发展挑战方面发挥的作用。在系列片中,诺为泰着重介绍了与Tune Therapeutics公司的紧密合作,双方携手推进慢性乙型肝炎功能性治愈研究。全球有近3亿人患有慢性乙型肝炎。诺为泰作为全球乙肝临床试验领域的重要参与者,凭借深厚的专业积淀和国际执行能力,助力申办方加速药物开发和上市进程。 该专题片拍摄于新西兰,当地约有10万名乙肝患者。国际知名肝病学家Edward Gane教授在片中介绍了诺为泰与生物技术公司和中小型制药企业的合作模式。专题片生动呈现了诺为泰如何整合专家资源、精准锁定受试者群体,依托在亚太地区、欧洲和北美地区建立的高效临床试验基础设施,加速临床开发进程。同时,也凸显了诺为泰...
-
New Study Finds Masimo SedLine® Brain Function Monitoring Offers Significant Advantages During Pediatric Anesthesia
NEUCHATEL, Switzerland--(BUSINESS WIRE)--A new study found that EEG-guided anesthesia using Masimo SedLine® improved anesthesia administration in children undergoing surgery....